Similar to the results from the entire CLL population, DNA damage protein expression patterns were prognostic (p = 0.03) for overall survival in patients treated with FCR but not in patients treated with BTK inhibitors (Figure 4); although, five of six deaths in BTKi treated patients were in C1 and C2. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.